Integrated Diagnostics Holdings Plc Notice of results
19 August 2020
(London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), IDHC on the London Stock Exchange, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, will publish its unaudited results for the first half ended 30 June 2020 on Wednesday, 2 September 2020 at 7am (UK).
An analyst and investor call will be hosted at 2pm (UK) | 3pm (Egypt) on Wednesday, 2 September 2020. A live audio webcast can be accessed at this link and you may dial in using the conference call details below:
• Access code: 257185
• UK dial in: (Toll free) 0800 640 6441 / (Int'l) +44 20 3936 2999
• USA dial in: (Toll free) +1 855 9796 654 / (Int'l) +1 646 664 1960
• UAE dial in: (Toll free) 800 0357 04553
Contact
IDH |
|
Nancy Fahmy Investor Relations Director |
+20 (0)12 2255 7445 |
|
|
About Integrated Diagnostics Holdings
IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 462 branches as of 30 June 2020, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.